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In a recent issue of Breast Cancer Research, Watson and 
Gusterson wrote a viewpoint article [1] about our 
strategy for developing a prophylactic breast cancer 
vaccine [2]. Th  e authors base much of their view on 
several misconceptions and misrepresentations that we 
wish to clarify.
We did not immunize mice with an antibody as the 
authors claim in their abstract. We immunized mice with 
a single injection of whole recombinant mouse α-lact-
albumin protein, and this single immunization provided 
highly signiﬁ   cant protection and therapy against the 
growth of tumors in several widely used mouse models 
for breast cancer.
Th   e authors indicate that our ‘approach was based on 
the hypothesis that removal of an organ will provide 
protection against cancer developing in that organ’ [1]. 
Th  e notion that excised organs have decreased risk for 
developing tumors is obviously simplistic and mis-
represents our actual hypothesis stated in the ﬁ  rst 
sentence of our article: ‘a full-strength autoimmune 
attack suﬃ     cient to induce organ-speciﬁ   c failure may 
provide protection and therapy against tumors derived 
from the targeted organ’ [2].
Th   e viewpoint questions the eﬃ   cacy of our strategy by 
claiming that ‘milk proteins are expressed in the gland 
with every oestrus cycle’ [1] but fails to indicate that α-
lactalbumin is not one of these milk proteins, because its 
expression in mice occurs only during late stages of 
gestation and reaches maximal expression only upon 
lactation [3].
Th   e authors cite two studies supporting their contention 
that α-lactalbumin is not expressed in human breast 
tumors but fail to cite 11 other studies showing that α-
lactalbumin is expressed in human breast tumors [4-14]. 
Th   is focus on target expression in mature tumors is moot 
since prophylactic vaccination requires eﬀ  ective targeting 
of proteins expressed in the emerging developing tumor 
perhaps as early as the initial dysplastic stages and not in 
the fully evolved primary and metastatic tumors.
In regard to the signiﬁ  cant inhibition of 4T1 breast 
tumor growth that we observed in α-lactalbumin-
vaccinated BALB/c mice, the authors state: ‘If the 
experiments had been continued for longer than 32 days, 
it seems very likely that there would be no real diﬀ  erence 
between the immunised mice and mock-immunised mice 
in terms of tumour burden’ [1]. We disagree with the 
authors’ speculation about what would have occurred 
since inhibition in growth of primary 4T1 tumors is more 
often associated with decreased metastasis and overall 
increased survival [15].
Perhaps the biggest misconception was the authors’ 
belief that the target population for our vaccine will be 
teenage girls. We have never proposed this. Th   e design of 
our vaccine was based on two complementary events that 
take place in women as they age, namely an increasing 
risk for developing breast cancer and a corresponding 
decreasing need for using the aging breast and its retired 
breast-speciﬁ   c proteins for lactation. Th  us, our target 
population has always been women who are more than 
40 years old and has never been teenagers as assumed by 
the authors. Th   is is clearly stated in the last sentence of 
our abstract [2].
Finally, we agree with the authors that women diﬀ  er 
considerably from mice and that there is legitimate 
concern that α-lactalbumin vaccination may target 
lactational foci in breasts of non-lactating women. 
However, the authors failed to indicate that, in the study 
they cited [16], there was no quantiﬁ   cation of the 
frequency of such foci and that the appearance of these 
foci in the breasts of non-lactating women was 
signiﬁ   cantly associated with the use of contraceptive 
hormones available in the late 1970s. We believe that the 
concern regarding inﬂ  ammatory consequences in vacci-
nating women in their 40s is real but should be resolved 
in phase I safety trials and not in a selective interpretation 
of old, controversial, and sometimes conﬂ  icting literature 
focused on protein expression in mature tumors rather 
than in the targeted emerging tumor and on non-quanti-
tative studies involving women taking contraceptive sex 
hormones. © 2010 BioMed Central Ltd
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© 2010 BioMed Central LtdWe remain delighted that our prototypic embryonic 
vaccine and the implications of our overall strategy for 
developing a much-needed safe and eﬀ  ective prophylaxis 
against breast cancer by extending vaccine target 
selection to retired self-proteins have resonated globally 
and stirred the hopes of so many breast cancer patients 
around the world.
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